Literature DB >> 19326700

[Cognitive impairment and parkinsonism due to use of sodium valproate].

L Schreur1, C W Middeljans-Tijssen, G J D Hengstman, M G M Olde Rikkert.   

Abstract

Two patients presented with progressive cognitive impairment and parkinsonism related symptoms while being treated with sodium valproate. Both patients suffered from progressive cognitive decline and mobility disorders with an insidious onset over a period of months to years. After discontinuation of sodium valproate both debilitating symptoms resolved nearly completely. There is a growing prevalence and incidence of epilepsy above the age of 60 and a great number of these patients are on sodium valproate treatment. All clinicians treating elderly patients should be aware of the fact that this treatment can cause reversible cognitive decline and parkinsonism probably due to impairment of mitochondrial complex I function. Discontinuation of sodium valproate is strongly recommended in all patients with development of cognitive impairment or parkinsonism or both during sodium valproate treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326700     DOI: 10.1007/bf03088474

Source DB:  PubMed          Journal:  Tijdschr Gerontol Geriatr        ISSN: 0167-9228


  2 in total

1.  Investigation of the risk of valproic acid-induced tremor: clinical, neuroimaging, and genetic factors.

Authors:  Lili Lan; Xu Zhao; Si Jian; Cun Li; Man Wang; Qing Zhou; Shanshan Huang; Suiqiang Zhu; Huicong Kang; Heidi E Kirsch
Journal:  Psychopharmacology (Berl)       Date:  2021-10-30       Impact factor: 4.530

2.  Possible sertraline-induced extrapyramidal adverse effects in an adolescent.

Authors:  Lian-Fang Wang; Jin-Wen Huang; Si-Yang Shan; Jia-Hong Ding; Jian-Bo Lai; Yi Xu; Shao-Hua Hu
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-06       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.